Portfolio Snapshots

We are an international equities manager, and we invest with a truly global outlook.

Here is a snapshot of the current portfolio disposition of our flagship Platinum Trust Funds and their key holdings.

Platinum International Health Care Fund

Platinum International Health Care Fund invests in health care companies from around the world, ranging from those engaged in early exploratory research to those providing health care services directly to consumers.

Established in 2003, the fund now has A$257.7 million under management^ and a track record of achieving 10.0% compound return annually since inception (on 10/11/2003).*

Platinum International Health Care Fund provides exposure to companies engaged in the provision of a wide range of products and services within the global healthcare ecosystem. It invests in multinational pharmaceuticals as well as emerging biotechs with cutting-edge R&D; hospital chains and nursing care operators as well as providers of diagnostic and laboratory technologies; health insurers as well as healthcare software providers.

Industry Breakdown1
SectorLong %Net %
Health Care 78.7 70.6
Consumer Staples 0.9 0.9
Health Care 78.7 70.6
Consumer Staples 0.9 0.9
Top 10 Positions3
StockCountryIndustry%
SpeeDx Pty Ltd Australia Health Care Providers 3.6
Roche Holding AG Switzerland Pharmaceuticals 3.0
Sanofi SA France Pharmaceuticals 2.9
Quanterix Corp USA Pharmaceuticals 2.8
Moderna Inc USA Pharmaceuticals 2.6
Nanostring Technologies Inc USA Health Equipment & Services 2.5
Gilead Sciences Inc USA Biotechnology 2.1
Takeda Pharmaceutical Co Ltd Japan Pharmaceuticals 2.1
Zai Lab Ltd China Biotechnology 2.1
UCB SA Belgium Pharmaceuticals 2.0
Disposition of Assets2
Long %Net %Currency%
Australia 13.6 13.1 3.4
Belgium 2.8 2.8 -
Canada 0.1 0.1 0.1
China Ex PRC 2.4 2.0 -
Denmark 0.8 0.8 0.8
France 3.7 3.4 -
Germany 2.9 2.9 -
Japan 3.6 3.4 13.6
Korea - (1.6) (1.6)
Netherlands 1.4 1.4 -
Singapore 0.5 0.5 -
Spain 1.4 1.4 -
Sweden 1.9 1.9 2.1
Switzerland 4.8 4.8 8.4
United Kingdom 3.6 3.6 8.5
United States 36.1 31.0 51.0
Euro Currency - - 11.5
Hong Kong Dollar - - 0.3
Norwegian Krone - - 1.9
Long: 64 stocks, 1 option. Short: 17 stocks.
Top 10 Positions3
StockCountryIndustry%
SpeeDx Pty Ltd Australia Health Care Providers 3.6
Roche Holding AG Switzerland Pharmaceuticals 3.0
Sanofi SA France Pharmaceuticals 2.9
Quanterix Corp USA Pharmaceuticals 2.8
Moderna Inc USA Pharmaceuticals 2.6
Nanostring Technologies Inc USA Health Equipment & Services 2.5
Gilead Sciences Inc USA Biotechnology 2.1
Takeda Pharmaceutical Co Ltd Japan Pharmaceuticals 2.1
Zai Lab Ltd China Biotechnology 2.1
UCB SA Belgium Pharmaceuticals 2.0
All data as at [28 February 2019] .
  1. “Long %” represents the Fund’s effective exposures to the relevant sectors as a percentage of the Fund’s NAV, taking into account direct stock holdings and long derivative positions (stocks and indices). “Net %” represents the Fund’s net exposures to the relevant sectors as a percentage of the Fund’s NAV, taking into account direct stock holdings and both long and short derivative positions (stocks and indices).
  2. “Long %” represents the Fund’s effective exposures to the relevant regions as a percentage of NAV through stock holdings and long derivatives (stocks and indices). “Net %” represents the Fund’s net exposures to the relevant regions as a percentage of NAV through stock holdings and both long and short derivatives (stocks and indices). “Currency %” represents the Fund’s effective exposures to the relevant currencies as a percentage of NAV through stock holdings, cash and the use of derivatives.
  3. The “Top 10 Positions” table shows the Fund’s top 10 long stock positions as a percentage of the Fund's NAV, taking into account direct stock holdings and long derivative positions.